MAPT and Alzheimer disease: Anti-Aβ and tau immunotherapies have paved the way in supporting the hypothesis that the removal of pathogenic proteins in AD is disease-modifying and potentially even preventative, giving further validity to TPD as an approach for the treatment of AD.